Guidance Updates -- Full-year 2025 revenue growth guidance was narrowed to 7.4%-8%, with Adjusted EPS guidance was set at $16 ...
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug ...
Laboratory Corporation of America Holdings, Inc., or Labcorp LH, recently launched a new, FDA-cleared blood test for risk assessment and clinical management of severe preeclampsia. The preeclampsia is ...
Zacks Investment Research on MSN
LH Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down
Labcorp Holdings LH, or Labcorp, reported adjusted earnings per share (EPS) of $4.18 for the third quarter of 2025. The ...
Laboratory Corporation of America Holdings LH, popularly known as LabCorp, recently launched the Neurofilament Light Chain (NfL) blood test to facilitate the detection and verification of the signs of ...
According to the College of Obstetricians and Gynecologists, female fertility begins to decline by age 30, and by 45, the chances of getting pregnant naturally are unlikely. But that doesn’t mean you ...
Labcorp forecast lower annual revenue growth for its contract research unit on Tuesday, as a prolonged funding crunch continues to weigh on its early-stage drug development clients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback